Oral NaV1.8 Inhibitor Designated Breakthrough Tx for Severe Acute Pain

The Food and Drug Administration has granted Breakthrough Therapy designation to VX-548 for the treatment of moderate to severe acute pain.

Related Keywords

,Carmen Bozic ,Global Medicines Development ,Drug Administration ,Breakthrough Therapy ,Pain Intensity Difference ,Executive Vice President ,Medical Affairs ,Chief Medical Officer ,